AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
+2.12 (+1.21%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close174.92
Bid177.10 x 200
Ask177.60 x 3200
Day's Range174.14 - 177.41
52 Week Range145.12 - 191.10
Avg. Volume2,711,639
Market Cap128.515B
PE Ratio (TTM)15.99
EPS (TTM)11.07
Earnings DateJan 31, 2018 - Feb 5, 2018
Forward Dividend & Yield5.28 (2.98%)
Ex-Dividend Date2017-11-16
1y Target Est190.55
Trade prices are not sourced from all markets
  • Biopharma wins in Trump tax bill
    Yahoo Finance Video6 days ago

    Biopharma wins in Trump tax bill

    One sector that's poised to win big in the Trump tax bill, biopharma. Yahoo Finance's Seana Smith, Andy Serwer and Melody Hahm discuss.

  • 3 Attractive Income Stocks Whose Dividends Could Double
    Motley Fool13 hours ago

    3 Attractive Income Stocks Whose Dividends Could Double

    These stocks have great dividends. And they should only get better.

  • Beware: Price Wars For Big Pharma, Biotech Companies On Horizon
    Investor's Business Daily2 days ago

    Beware: Price Wars For Big Pharma, Biotech Companies On Horizon

    The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.

  • Investopedia2 days ago

    Biotech Celgene May Rise 35% In 2018

    A peer analysis of biotechnology companies suggests Celgene's stock will climb in 2018.

  • Barrons.com2 days ago

    Amgen: Why Goldman Just Wants to Be Friends

    Goldman Sachs is out with an update on healthcare ahead of the new year, and while analyst Jami Rubin and her team still bullish on Amgen (AMGN), she removed it from the firm's Conviction Buy list. Rubin still reiterated a Buy rating on the stock and $218 price target, writing that she believes new products will offset erosion of its legacy biologics, like Neulasta, which is facing increasing competition,  and continue to drive low-single-digit growth.

  • Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : December 15, 2017
    Capital Cube3 days ago

    Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : December 15, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Amgen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • PR Newswire3 days ago

    Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral

    CAMBRIDGE, Mass., Dec. 14, 2017 /PRNewswire/ -- Amgen (AMGN) and LabCentral today announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge R&D and Operations facility on Dec. 11, 2017.

  • Barrons.com4 days ago

    Amgen: Even Biotech Stocks Boost Their Dividends

    Biotech giant Amgen (AMGN) is providing some holiday cheer to investors with a 15% dividend increase. Last year Amgen paid out about one-third of its earnings in dividends. Shares of Amgen have gained 0.3% to $176.79 at 12:20 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has risen 0.3% to $106.09.

  • CNBC4 days ago

    Stocks making the biggest moves premarket: HON, LLY, AMGN, TM, HD & more

    These are the stocks posting the largest moves before the bell.

  • PR Newswire5 days ago

    Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend

    THOUSAND OAKS, Calif., Dec. 12, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the first quarter of 2018. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

  • Jim Simons: Pioneer Quant Manager
    GuruFocus.com5 days ago

    Jim Simons: Pioneer Quant Manager

    A brilliant mathematician turned his mind to investing, and emerged a big winner

  • Reuters6 days ago

    Amgen's Kyprolis improves overall survival in blood cancer patients

    Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer. Kyprolis when used with two standard of care drugs, dexamethasone and Celgene Corp's Revlimid, reduced the risk of death by 21 percent and extended survival by 7.9 months, compared with patients treated with the two drugs alone, the company said. The study, ASPIRE, tested Kyprolis, chemically known as carfilzomib, in multiple myeloma patients whose cancer had relapsed following prior treatment or did not respond to treatment.

  • PR Newswire6 days ago

    KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial

    Results Highlighted During Oral Presentation at ASH 2017 Addition of KYPROLIS to Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone Regulatory ...

  • PR Newswire6 days ago

    Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires

    THOUSAND OAKS, Calif., Dec. 11, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the Southern California wildfires. Of this commitment, $200,000 will be directed to the United Way of Ventura County to support their immediate relief efforts.

  • MarketWatch7 days ago

    Republican tax bill makes big winners of Amgen, Gilead and other drugmakers

    Of all U.S. companies, drugmakers have some of the most cash held outside the country.

  • TheStreet.com7 days ago

    Deciphering Wall Street's Differing Views of Amgen

    What to make of the divergent views of Amgen's shares.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.


  • Dec. 7 Forum Update: "Retail Sector" Edition
    GuruFocus.com10 days ago

    Dec. 7 Forum Update: "Retail Sector" Edition

    A summary of Forum activity from November

  • PR Newswire10 days ago

    New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers

    THOUSAND OAKS, Calif., Dec. 7, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that new clinical data and analyses from 33 abstracts, including six oral presentations, evaluating approved medicines and investigational immuno-oncology agents from the Company's robust hematology portfolio and pipeline will be presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Dec. 9-12, 2017. The breadth and depth of data to be presented at ASH highlight Amgen's commitment to advancing treatment options for patients with some of the most difficult-to-treat blood cancers and disorders. Notably at ASH, positive overall survival (OS) results from the Phase 3 ASPIRE trial will be detailed for the first time in an oral presentation, which showed the addition of KYPROLIS® (carfilzomib) to lenalidomide and dexamethasone (KRd) significantly extended OS versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.

  • PR Newswire11 days ago

    Amgen To Webcast Investor Call At ASH 2017

    THOUSAND OAKS, Calif., Dec. 6, 2017 /PRNewswire/ -- Amgen (AMGN) will host a webcast call for the investment community at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition on Saturday, Dec. 9, 2017, at 11:30 a.m. ET. David M. Reese, M.D., senior vice president of Translational Sciences and Oncology at Amgen, together with other members of Amgen's management team and a clinical investigator, will participate to discuss the Company's oncology program, including our BiTE® immunotherapy platform. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website,, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.

  • Capital Cube11 days ago

    Amgen, Inc. – Value Analysis (NASDAQ:AMGN) : December 6, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Amgen, Inc. a score of 47. Our analysis is based on comparing Amgen, Inc. with the following peers – Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Celgene Corporation, Gilead Sciences, Inc., AbbVie, Inc., Biogen Inc., Alexion Pharmaceuticals, Inc., Roche Holding Ltd Genusssch. and Johnson & ... Read more (Read more...)

  • Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data
    Zacks12 days ago

    Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data

    Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.

  • Investopedia12 days ago

    Biotech Stocks May See a New M&A Wave in 2018

    Struggling biotech giants could bolster their stocks in 2018 if they acquire smaller drug companies.

  • Market Realist13 days ago

    What Analysts Recommend for Pfizer in November 2017

    23 analysts were tracking Pfizer in November 2017. One analyst recommended a “strong buy,” while 11 analysts recommended a “buy.”